Drug Discovery · Cambridge, MA · Founded 2015 · Privately Held (backing)
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. Parabilis Medicines is based in Cambridge, MA and was founded in 2015. It is valued at about $920 million as of Oct 2026, set by institutional fund marks. It has raised $812 million across 3 recorded rounds; the latest was a $305 million Series F in Jan 2026.
PMV mark · valuation
$920.0M
Oct 2026
Priced at
its later-stage round
Jan 2026
Total raised
$812.0M
Last round
Later Stage VC (Series F)
Jan 2026
Team — not yet on record
No current team members for Parabilis Medicines are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Parabilis Medicines with a free account
·The complete investor list: 38 names
·Watch Parabilis Medicines: the Monday email on marks, rounds and moves
